Abstract 103P
Background
Texture analysis is used to assess the homogeneous or nonhomogenous information of the selected regions, and provides many quantitative and semiquantitative parameters that are able to closely reflect the characteristics of cancer lesions. This study was designed to estimate the clinical significance of the contrast-enhanced computed tomograpgy (CT) textural features for prediction of survival in colorectal cancer (CRC) patients receiving targeted therapy (bevacizumab and cetuximab).
Methods
The LifeX software was used to extract the textural parameters of the tumor lesions in the contrast-enhanced CT. Univariate and multivariate analyses using the Cox proportional hazards model were performed to assess the prognostic value of textural parameters.
Results
Eighty CRC patients receiving targeted therapy (bevacizumab 42; cetuximab 38) were included. In the multivariate analysis, 8 textural parameters were revealed to be independent predictors (p < 0.05) of progression-free survival (PFS) and overall survival (OS), including Skewness, Kurtosis, Homogeneity, Energy and Entropy of Gray-level co-occurrence matrix (GLCM), Long-run emphasis (LRE), Long-run high gray-level emphasis (LRHGE), and Contrast. Furthermore, Sphericity, Compacity, Long-run low gray-level emphasis (LRLGE), Low gray-level zone emphasis (LGZE) and Short-zone low gray-level emphasis (SZLGE) were show to be significantly associated with PFS, while Entropy-Histogram and Energy-Histogram, Dissimilarty, Short-run emphasis (SRE), Short-run low gray-level emphasis (SRLGE), Run percentage (RP), Long-zone emphasis (LZE), Long-zone low gray-level emphasis (LZLGE) and Long-zone high gray-level emphasis (LZHGE) were significantly associated with OS.
Conclusions
In conclusion, our study provides preliminary evidences that several radiomic parameters of tumor lesions derived from CT images were prognostic factors and predictive markers for CRC patients who are candidates for targeted therapy (bevacizumab and cetuximab).
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
329P - High-level expression of HDAC10 is associated with PD-L1 expression and poor prognosis in patients with non-small cell lung cancer receiving pulmonectomy
Presenter: Xiaomei Liu
Session: Poster display session
Resources:
Abstract
331P - A retrospective analysis of immune checkpoint therapy in patients with non-small cell lung cancer: Focus on thyroid disorder
Presenter: Sawana Ono
Session: Poster display session
Resources:
Abstract
332P - Analyse the association between adverse events (AEs) and survival in patients treated with immune checkpoint inhibitors (ICIs)
Presenter: Chi-yuan Cheng
Session: Poster display session
Resources:
Abstract
333P - Study of searching on efficacy of immune checkpoint inhibitor for the non-small cell lung cancer using FDG-PET/CT and thallium SPECT
Presenter: KAYOKO Kibata
Session: Poster display session
Resources:
Abstract
334P - Incidence and characteristic of adrenal insufficiency due to immune checkpoint inhibitors therapy
Presenter: Daisuke Etoh
Session: Poster display session
Resources:
Abstract
335P - PD-L1 profile of nasopharyngeal cancer patients in Indonesia
Presenter: Handoko Handoko
Session: Poster display session
Resources:
Abstract
336P - Pembrolizumab plus chemotherapy versus pembrolizumab monotherapy for PD-L1-positive advanced non-small cell lung cancer in the real world
Presenter: Jun Sugisaka
Session: Poster display session
Resources:
Abstract
337P - Neutrophil-to-Lymphocyte ratio as a predictive factor for hyperprogressive disease in NSCLC patients treated with immune checkpoint inhibitor
Presenter: Ryo Takahashi
Session: Poster display session
Resources:
Abstract
338P - A new insight into tumour immune-evasion: Crosstalk between cancer stem cells and T regulatory cells
Presenter: Abhishek Dutta
Session: Poster display session
Resources:
Abstract
339TiP - PACIFIC-5: Phase III study of durvalumab after either concurrent or sequential chemoradiotherapy (CRT) in patients with stage III NSCLC
Presenter: Yi-Long Wu
Session: Poster display session
Resources:
Abstract